Beneficial effects of luseogliflozin on lipid profile and liver function in patients with type 2 diabetes mellitus (BLUE trial): a single-center, single-arm, open-label prospective study

BACKGROUND: Arteriosclerosis and non-alcoholic fatty liver disease are major complications of diabetes mellitus. Hyperglycemia, insulin resistance, obesity, and metabolic syndrome are associated with the progression of these complications. Sodium-glucose transporter 2 inhibitors such as luseoglifloz...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajika, Yuriko, Kawaguchi, Yuji, Hamazaki, Kenji, Kumeda, Yasuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173585/
https://www.ncbi.nlm.nih.gov/pubmed/37165443
http://dx.doi.org/10.1186/s13098-023-01074-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173585/
https://www.ncbi.nlm.nih.gov/pubmed/37165443
http://dx.doi.org/10.1186/s13098-023-01074-1

Ejemplares similares